DNM2 and neoplasm: In a prostate cancer mouse model in which formation of subcutaneous tumors are induced after injection of human prostatic adenocarcinoma cells, intratumoral injection of a DNM2 inhibitor (N’-[4-(dipropylamino)benzylidene]-2-hydroxybenzohydrazide, DBHA) rapidly reduces tumor size without apparent adverse effect [89].